HK1211296A1 - Preparation, uses and solid forms of obeticholic acid - Google Patents

Preparation, uses and solid forms of obeticholic acid

Info

Publication number
HK1211296A1
HK1211296A1 HK15112051.4A HK15112051A HK1211296A1 HK 1211296 A1 HK1211296 A1 HK 1211296A1 HK 15112051 A HK15112051 A HK 15112051A HK 1211296 A1 HK1211296 A1 HK 1211296A1
Authority
HK
Hong Kong
Prior art keywords
preparation
solid forms
obeticholic acid
obeticholic
acid
Prior art date
Application number
HK15112051.4A
Other languages
English (en)
Chinese (zh)
Inventor
‧施泰納
‧維納倫德普爾森
‧喬利博瓦
‧雷沃林斯基
‧格羅斯
‧夏普
‧迪巴斯-費希爾
‧埃伯林
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48741553&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1211296(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Publication of HK1211296A1 publication Critical patent/HK1211296A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
HK15112051.4A 2012-06-19 2015-12-07 Preparation, uses and solid forms of obeticholic acid HK1211296A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261661531P 2012-06-19 2012-06-19
PCT/US2013/046150 WO2013192097A1 (en) 2012-06-19 2013-06-17 Preparation, uses and solid forms of obeticholic acid

Publications (1)

Publication Number Publication Date
HK1211296A1 true HK1211296A1 (en) 2016-05-20

Family

ID=48741553

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15112051.4A HK1211296A1 (en) 2012-06-19 2015-12-07 Preparation, uses and solid forms of obeticholic acid

Country Status (25)

Country Link
US (8) US9238673B2 (es)
EP (4) EP3336097B1 (es)
JP (6) JP2015521621A (es)
KR (4) KR20190121871A (es)
CN (2) CN111228278A (es)
AU (5) AU2013277429B2 (es)
BR (2) BR122016011808B1 (es)
CA (3) CA2877122C (es)
CL (2) CL2014003475A1 (es)
CO (1) CO7240414A2 (es)
DK (1) DK3336097T3 (es)
EA (2) EA201990211A1 (es)
ES (1) ES2822375T3 (es)
HK (1) HK1211296A1 (es)
IL (3) IL236231A0 (es)
IN (1) IN2014MN02561A (es)
MX (2) MX365059B (es)
NZ (3) NZ719360A (es)
PH (1) PH12014502835A1 (es)
PL (1) PL3336097T3 (es)
PT (1) PT3336097T (es)
SG (3) SG11201408501UA (es)
SI (1) SI3336097T1 (es)
TW (1) TWI673284B (es)
WO (1) WO2013192097A1 (es)

Families Citing this family (163)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL157816A0 (en) 2001-03-12 2004-03-28 Roberto Pellicciari Steroids as agonists for fxr
US9719068B2 (en) 2010-05-06 2017-08-01 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
US9982008B2 (en) 2012-06-19 2018-05-29 Intercept Pharmaceuticals, Inc. Preparation and uses of obeticholic acid
EP3336097B1 (en) 2012-06-19 2020-08-19 Intercept Pharmaceuticals, Inc. Preparation of the non-crystalline form of obeticholic acid
BR112015012312A2 (pt) * 2012-11-28 2017-07-11 Intercept Pharmaceuticals Inc método de tratamento, redução do risco, prevenção ou alívio de uma afecção ou doença pulmonar em um sujeito; método de redução ou supressão de inflamação no pulmão em um sujeito; e método de promoção de reparo pulmonar em um sujeito
US9814733B2 (en) * 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
EP2986624B1 (en) 2013-04-17 2020-03-25 Sage Therapeutics, Inc. 19-nor neuroactive steroids for methods of treatment
JP6470258B2 (ja) 2013-04-17 2019-02-13 セージ セラピューティクス， インコーポレイテッド １９−ノルｃ３，３−ジ置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法
WO2014169831A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof
US20160068563A1 (en) 2013-04-17 2016-03-10 Boyd L. Harrison 19-nor neuroactive steroids and methods of use thereof
DK3021852T3 (da) 2013-07-19 2021-03-15 Sage Therapeutics Inc Neuroaktive steroider, sammensætninger og anvendelser deraf
WO2015027227A1 (en) 2013-08-23 2015-02-26 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
AU2015267148B2 (en) 2014-05-28 2021-07-29 Children's Hospital Medical Center Methods and systems for converting precursor cells into gastric tissues through directed differentiation
CN106661079B (zh) 2014-05-29 2019-03-01 巴尔制药有限公司 用于治疗和/或预防fxr和tgr5/gpbar1介导的疾病的胆烷衍生物
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
WO2016045480A1 (zh) * 2014-09-28 2016-03-31 上海源力生物技术有限公司 一种奥贝胆酸的制备方法
JP6742308B2 (ja) 2014-10-16 2020-08-19 セージ セラピューティクス， インコーポレイテッド Ｃｎｓ障害を処置するための組成物および方法
TWI762436B (zh) 2014-10-16 2022-05-01 美商賽吉醫療公司 用於治療中樞神經系統（ｃｎｓ）病症之組合物及方法
EP3207123A1 (en) 2014-10-17 2017-08-23 Children's Hospital Center D/b/a Cincinnati Children's Hospital Medical Center In vivo model of human small intestine using pluripotent stem cells and methods of making and using same
RU2017118569A (ru) 2014-11-06 2018-12-06 Энанта Фармасьютикалс, Инк. Аналоги желчных кислот как агонисты fxr/tgr5 и способы их применения
EP3221334B1 (en) 2014-11-19 2020-02-19 Nzp Uk Limited 6.alpha.-alkyl-6,7-dione steroids as intermediates for the production of steroidal fxr modulators
WO2016079519A1 (en) * 2014-11-19 2016-05-26 Dextra Laboratories Limited 6.alpha.-alkyl-3,7-dione steroids as intermediates for the production of steroidal fxr modulators
WO2016079517A1 (en) 2014-11-19 2016-05-26 Dextra Laboratories Limited 6-alkyl-7-hydroxy-4-en-3-one steroids as intermediates for the production of steroidal fxr modulators
WO2016079518A1 (en) 2014-11-19 2016-05-26 Dextra Laboratories Limited 5.beta.-6-alkyl-7-hydroxy-3-one steroids as intermediates for the production of steroidal fxr modulators
RU2017121457A (ru) 2014-11-26 2018-12-26 Энанта Фармасьютикалс, Инк. Аналоги желчной кислоты в качестве агонистов fxr/tgr5 и способы их применения
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
US11578097B2 (en) 2014-11-26 2023-02-14 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
DK3224269T3 (da) 2014-11-27 2020-05-25 Sage Therapeutics Inc Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser
CN105777835B (zh) * 2014-12-25 2020-02-14 重庆药友制药有限责任公司 一种制备鹅去氧胆酸类似物的方法
CN105801653B (zh) * 2014-12-30 2018-04-17 苏州晶云药物科技有限公司 奥贝胆酸的晶型a及其制备方法
CN105859814A (zh) * 2015-01-23 2016-08-17 江苏奥赛康药业股份有限公司 一种奥贝胆酸化合物及其药物组合物
DK3250210T3 (da) 2015-01-26 2021-03-08 Sage Therapeutics Inc Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser
SG11201706347SA (en) 2015-02-06 2017-09-28 Intercept Pharmaceuticals Inc Pharmaceutical compositions for combination therapy
AU2016219266A1 (en) 2015-02-11 2017-08-10 Enanta Pharmaceuticals, Inc. Bile acid analogs as FXR/TGR5 agonists and methods of use thereof
CN105985395A (zh) * 2015-02-13 2016-10-05 江苏奥赛康药业股份有限公司 一种奥贝胆酸化合物及含有该化合物的药物组合物
CN105985396A (zh) * 2015-02-16 2016-10-05 苏州泽璟生物制药有限公司 氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物
ES2935476T3 (es) 2015-02-20 2023-03-07 Sage Therapeutics Inc Esteroides neuroactivos, composiciones y usos de los mismos
WO2016144946A1 (en) * 2015-03-09 2016-09-15 Intercept Pharmaceuticals, Inc. Methods for modulating bone density
HUE054960T2 (hu) 2015-03-31 2021-10-28 Enanta Pharm Inc Epesav származékok, mint az FXR/TGR5 agonista és annak felhasználási módszerei
CN107613986A (zh) 2015-04-07 2018-01-19 英特塞普特医药品公司 用于组合疗法的药物组合物
CN105777836A (zh) * 2015-04-09 2016-07-20 厦门蔚扬药业有限公司 奥贝胆酸的多晶型物及其制备方法
WO2016168553A1 (en) * 2015-04-17 2016-10-20 Concert Pharmaceuticals, Inc. Deuterated obeticholic acid
PE20180690A1 (es) * 2015-04-27 2018-04-23 Intercept Pharmaceuticals Inc Composiciones de acido obeticolico y metodos de uso
CN106290594B (zh) * 2015-05-27 2020-07-17 中美华世通生物医药科技（武汉）有限公司 测定奥贝胆酸片溶出含量的方法
CN105294801A (zh) * 2015-07-02 2016-02-03 扬子江药业集团南京海陵药业有限公司 6-乙基鹅去氧胆酸异构体的合成及其分离测定方法
CZ2015504A3 (cs) 2015-07-16 2017-01-25 Zentiva, K.S. Krystalické formy obeticholové kyseliny
EP3124080A1 (en) * 2015-07-28 2017-02-01 Merz Pharma GmbH & Co. KGaA Semisynthetic bile acids for injection lipolysis
CN105085597B (zh) * 2015-08-28 2017-03-29 成都百裕制药股份有限公司 一种无定型奥贝胆酸的制备方法
CN106478756A (zh) * 2015-09-02 2017-03-08 中美华世通生物医药科技（武汉）有限公司 Oca-e单晶及其制备方法和用途
CA2998876A1 (en) * 2015-09-21 2017-03-30 Intercept Pharmaceuticals, Inc. Methods of promoting hepatic regeneration
KR20180052756A (ko) 2015-09-24 2018-05-18 인터셉트 파마슈티컬즈, 인크. 담즙산 유도체 제조를 위한 방법 및 중간체
BR112018006892B1 (pt) 2015-10-07 2023-04-11 Intercept Pharmaceuticals, Inc Composto, composição farmacêutica do mesmo e seus usos como moduladores do receptor farnesoide x
CN106589038A (zh) * 2015-10-15 2017-04-26 重庆医药工业研究院有限责任公司 一种制备3α,7α-二羟基-6α-乙基-5β-胆烷酸的方法
CN106589039B (zh) * 2015-10-15 2019-12-17 苏州朗科生物技术股份有限公司 一种奥贝胆酸的制备方法及相关化合物
CN106632564B (zh) * 2015-10-30 2021-04-13 苏州泽璟生物制药股份有限公司 奥贝胆酸盐及其无定形物和药物组合物
CN106668027A (zh) * 2015-11-05 2017-05-17 中美华世通生物医药科技（武汉）有限公司 奥贝胆酸药物组合物及其制备方法
CA3004275A1 (en) * 2015-11-06 2017-05-11 Intercept Pharmaceuticals, Inc. Methods for the preparation of obeticholic acid and derivatives thereof
CN106749466B (zh) * 2015-11-23 2019-05-21 南京济群医药科技股份有限公司 一种高纯度奥贝胆酸的制备方法
CN105315320B (zh) * 2015-11-30 2017-03-08 山东省药学科学院 一种制备奥贝胆酸的方法
CN106810587A (zh) * 2015-12-01 2017-06-09 中美华世通生物医药科技（武汉）有限公司 制备无定型奥贝胆酸的方法
CN106810586A (zh) * 2015-12-01 2017-06-09 中美华世通生物医药科技（武汉）有限公司 奥贝胆酸晶型ⅱ及其制备方法和用途
CN106822005A (zh) * 2015-12-03 2017-06-13 江苏先声药业有限公司 奥贝胆酸组合物及其制备方法
CN106854229A (zh) * 2015-12-08 2017-06-16 陈剑 一类脂肪酸盐,其制备及其在医药上的应用
CN105481925B (zh) * 2015-12-17 2018-06-22 南京济群医药科技股份有限公司 一种奥贝胆酸及其中间体的制备方法
AU2016375566A1 (en) * 2015-12-22 2018-07-05 Intercept Pharmaceuticals, Inc. Polymorphic crystalline forms of obeticholic acid
CN105399793A (zh) * 2015-12-24 2016-03-16 北京康立生医药技术开发有限公司 一种胆烷酸的制备方法
CN106916195A (zh) * 2015-12-25 2017-07-04 中美华世通生物医药科技（武汉）有限公司 奥贝胆酸中间体的纯化方法
WO2017115324A1 (en) 2016-01-01 2017-07-06 Lupin Limited Solid forms of obeticholic acid and processes thereof
CN105566429B (zh) * 2016-01-22 2020-12-01 南京长澳医药科技有限公司 一种奥贝胆酸1型的制备方法
CN105646633B (zh) * 2016-01-22 2020-05-26 南京长澳医药科技有限公司 一种制备奥贝胆酸1型的方法
CN105646634A (zh) * 2016-01-29 2016-06-08 中国药科大学 奥贝胆酸杂质的制备方法
US10519193B2 (en) 2016-02-02 2019-12-31 Shenzhen Targetrx, Inc. Steroidal compound, composition containing the same and use thereof
CN108697700B (zh) * 2016-02-04 2021-08-17 辛多美制药有限公司 氘代多潘立酮组合物和用于治疗病症的方法
US11168107B2 (en) 2016-02-10 2021-11-09 Dr. Reddy's Laboratories Limited Amine salt of obeticholic acid
US10323061B2 (en) 2016-02-23 2019-06-18 Enanta Pharmaceuticals, Inc. Heteroaryl containing bile acid analogs as FXR/TGR5 agonists and methods of use thereof
WO2017147137A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Benzoic acid derivatives of bile acid as fxr/tgr5 agonists and methods of use thereof
US10364267B2 (en) 2016-02-23 2019-07-30 Enanta Pharmaceuticals, Inc. Deuterated bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
CN107126419B (zh) * 2016-02-26 2020-06-19 石药集团中诺药业（石家庄）有限公司 一种奥贝胆酸片剂及其制备方法
CN106008639B (zh) * 2016-03-11 2019-01-08 深圳市塔吉瑞生物医药有限公司 用于预防或治疗fxr-介导疾病的胆烷酸化合物
CN105541953B (zh) * 2016-03-15 2017-11-21 成都市新功生物科技有限公司 一种高纯度奥贝胆酸的重结晶纯化方法
CN107188917A (zh) * 2016-03-15 2017-09-22 正大天晴药业集团股份有限公司 奥贝胆酸盐及其药物组合物
US11419878B2 (en) * 2016-03-28 2022-08-23 Intercept Pharmaceuticals, Inc. Medicine obtained by combining FXR agonist and ARB
US11161871B2 (en) 2016-03-31 2021-11-02 Jiangsu Hengrui Medicine Co., Ltd. Crystalline form of obeticholic acid and preparation method therefor
AU2017244982A1 (en) * 2016-03-31 2018-11-01 Intercept Pharmaceuticals, Inc. Film-coated tablet having high chemical stability of active ingredient
TW201735928A (zh) * 2016-03-31 2017-10-16 大日本住友製藥股份有限公司 溶出性優異之口服製劑
EP3228306A1 (en) 2016-04-04 2017-10-11 ratiopharm GmbH Complex compound comprising obeticholic acid and cyclodextrin and pharmaceutical formulation comprising the complex compound
CN109311933A (zh) 2016-04-04 2019-02-05 迪法玛弗朗西斯有限公司 制备法尼醇x受体激动剂的方法
TW201738254A (zh) 2016-04-19 2017-11-01 英特賽普醫藥品公司 奧貝膽酸及其衍生物之製備方法
CN116790476A (zh) 2016-05-05 2023-09-22 儿童医院医疗中心 用于体外制造胃底组织的方法和与其相关的组合物
CN105859817A (zh) * 2016-05-09 2016-08-17 成都宇西医药技术有限公司 一种制备3α-羟基-6-乙烯基-7-酮基-5β-胆烷酸的方法
CN107400154A (zh) * 2016-05-18 2017-11-28 北京凯因科技股份有限公司 一种制备3α,7α-二-羟基-6α-乙基-5β-胆烷酸的方法
GB201608776D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Methods and compounds
GB201608777D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Compounds
CN106046094A (zh) * 2016-05-30 2016-10-26 福建广生堂药业股份有限公司 一种奥贝胆酸二聚体杂质及其制备方法
CN105859818A (zh) * 2016-05-31 2016-08-17 四川瑞希康生物医药有限公司 一种奥贝胆酸α晶型及其制备方法、药物组合物和用途
CN109415405A (zh) 2016-06-01 2019-03-01 雷迪博士实验室有限公司 制备奥贝胆酸的方法
CN105997909A (zh) * 2016-06-02 2016-10-12 中国药科大学 一种奥贝胆酸口崩片及其制备方法
CA2968836A1 (en) 2016-06-13 2017-12-13 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
KR102269305B1 (ko) 2016-06-13 2021-06-25 길리애드 사이언시즈, 인코포레이티드 Fxr (nr1h4) 조정 화합물
CN106083971B (zh) * 2016-06-17 2017-11-14 苏州敬业医药化工有限公司 一种(E)‑3α‑羟基‑6‑亚乙基‑7‑酮‑5β‑胆烷‑24‑酸的制备方法
CZ2016385A3 (cs) 2016-06-28 2018-01-10 Zentiva, K.S. Způsoby přípravy intermediátů pro syntézu Obeticholové kyseliny
CN107540720B (zh) * 2016-06-29 2021-03-02 常州市第四制药厂有限公司 3α,7α-二羟基-6α-乙基-5β-胆烷酸晶型H及其制备方法和应用
IL309259A (en) 2016-07-11 2024-02-01 Sage Therapeutics Inc C17, C20 and C21 converted neuroactive steroids and methods of using them
CN107648190B (zh) * 2016-07-26 2021-04-27 海南先声药业有限公司 奥贝胆酸组合物及其制备方法
CN106279331B (zh) * 2016-07-27 2019-06-14 宋火良 胆酸类肝病治疗药物
CN107674106B (zh) * 2016-08-01 2021-06-22 华北制药集团新药研究开发有限责任公司 一种奥贝胆酸二聚体的制备方法
CN106279335A (zh) * 2016-08-12 2017-01-04 齐鲁制药有限公司 一种制备奥贝胆酸及其中间体的方法
EP3287467A1 (en) 2016-08-22 2018-02-28 ratiopharm GmbH Preparation of obeticholic acid comprising continuous flow process steps
CN107778339A (zh) * 2016-08-29 2018-03-09 鲁南制药集团股份有限公司 一种无定型奥贝胆酸的制备方法
CN115490744A (zh) * 2016-08-29 2022-12-20 山东新时代药业有限公司 一种3α-羟基-6α-乙基-7-酮-5β-胆-24-酸的制备方法
EP3293196A1 (en) 2016-09-09 2018-03-14 Hexal AG Process for purifying obeticholic acid
CN106478757B (zh) * 2016-09-27 2019-01-18 华南理工大学 一种3α,7α-二羟基-6α-乙基胆烷酸的制备方法
CA3038534A1 (en) * 2016-09-30 2018-04-05 Intercept Pharmaceuticals, Inc. Crystalline forms of a bile acid derivative
CN107976506B (zh) * 2016-10-25 2020-05-12 成都弘达药业有限公司 一种奥贝胆酸有关物质的检测方法
NZ753051A (en) 2016-11-04 2023-03-31 Children’S Hospital Medical Center Liver organoid compositions and methods of making and using same
MX2019006165A (es) * 2016-11-29 2019-10-14 Enanta Pharm Inc Proceso para la preparacion de derivados del acido biliar de las sulfonilureas.
JP7068305B2 (ja) 2016-12-05 2022-05-16 チルドレンズ ホスピタル メディカル センター 結腸オルガノイドならびにその作製方法および使用方法
WO2018104916A1 (en) * 2016-12-09 2018-06-14 Cadila Healthcare Limited Treatment for primary biliary cholangitis
CN108614038B (zh) * 2016-12-13 2022-05-17 亚宝药业集团股份有限公司 一种测定奥贝胆酸原料药有关物质的方法
CN106749472B (zh) * 2016-12-30 2019-02-22 江苏开元医药化工有限公司 一种3α-羟基-6α-乙基-7-酮-5β-胆烷-24-酸的制备方法
CN106645497A (zh) * 2017-01-03 2017-05-10 山东省药学科学院 一种奥贝胆酸及其制剂中有关物质的检测方法
CN110268128A (zh) 2017-01-18 2019-09-20 特里姆科有限公司 结构粘接复合材料
WO2018152171A1 (en) 2017-02-14 2018-08-23 Enanta Pharmaceuticals, Inc. Bile acid derivatives as fxr agonists and methods of use thereof
CN106892954B (zh) * 2017-02-23 2019-04-30 广州隽沐生物科技有限公司 奥贝胆酸的制备工艺
US20210139528A1 (en) * 2017-03-08 2021-05-13 Intercept Pharmaceuticals, Inc. Crystalline forms of obeticholic acid
CN110461328A (zh) 2017-03-28 2019-11-15 吉利德科学公司 治疗肝疾病的治疗组合
CN108659086A (zh) * 2017-03-29 2018-10-16 杭州源昶医药科技有限公司 一种奥贝胆酸的合成方法
MX2019011844A (es) 2017-04-07 2021-11-30 Enanta Pharm Inc Proceso para la preparación de derivados de ácidos biliares de sulfonil carbamato.
CN106986910A (zh) * 2017-04-19 2017-07-28 成都百特万合医药科技有限公司 奥贝胆酸中间体的制备方法
WO2018194426A1 (ko) * 2017-04-20 2018-10-25 대웅바이오 주식회사 연속흐름반응을 이용한 담즙산 유도체의 제조 방법
WO2018211413A1 (en) * 2017-05-15 2018-11-22 Dr. Reddy’S Laboratories Limited Solid forms of obeticholic acid and process for preparation
CZ2017298A3 (cs) 2017-05-26 2018-12-05 Zentiva, K.S. Amorfní formy obeticholové kyseliny
CN107286160A (zh) * 2017-06-05 2017-10-24 毛佳婧 一种抗肝炎药物的哌啶并吡啶并吡唑‑锌配合物的制备方法
US11364226B2 (en) 2017-06-30 2022-06-21 Cinrx Pharma, Llc Deuterated domperidone compositions, methods, and preparation
CN109280071A (zh) * 2017-07-19 2019-01-29 东莞东阳光药物研发有限公司 奥贝胆酸的晶型及其制备方法
AU2018307611A1 (en) 2017-07-24 2020-02-06 Intercept Pharmaceuticals, Inc. Isotopically labeled bile acid derivatives
JP6937893B2 (ja) 2017-08-03 2021-09-22 メディトックス インク． 胆汁酸類を製造するための方法
CN107383139A (zh) * 2017-08-09 2017-11-24 杭州和泽医药科技有限公司 一种3α‑羟基‑7‑氧代‑5β‑胆烷酸新衍生物制备奥贝胆酸的方法
CN109485687A (zh) * 2017-09-12 2019-03-19 成都弘达药业有限公司 奥贝胆酸的晶型j及其制备方法
US10611793B1 (en) 2017-11-27 2020-04-07 Teva Czech Industries S.R.O. Solid state forms of obeticholic acid salts
WO2019106043A1 (en) 2017-11-29 2019-06-06 Hexal Ag Pharmaceutical composition comprising obeticholic acid
KR20200096596A (ko) 2017-12-08 2020-08-12 세이지 테라퓨틱스, 인크. Cns 장애의 치료를 위한 중수소화 21 -[4-시아노-피라졸-1 -일]-19-노르-프레간-3. 알파-올-20-온 유도체
US11434256B2 (en) 2018-01-25 2022-09-06 Msn Laboratories Private Limited, R&D Center Process for the preparation of 3α,7α-dihydroxy-6α-ethyl-5β-cholan-24-oic acid
CN108440629A (zh) * 2018-03-16 2018-08-24 丽珠集团新北江制药股份有限公司 一种制备奥贝胆酸中间体及奥贝胆酸的方法
WO2019197962A1 (en) * 2018-04-09 2019-10-17 Biophore India Pharmaceuticals Pvt. Ltd Crystalline forms of (3α, 5β, 6α, 7α)-6-ethyl-3, 7-dihydroxycholan-24-oic acid (obeticholic acid) and processes thereof
CN110655550A (zh) * 2018-06-29 2020-01-07 江苏海悦康医药科技有限公司 (E)-3α-羟基-6-亚乙基-7-氧代-5β-胆甾烷-24-酸的制备方法
CN108794558B (zh) * 2018-07-03 2020-05-22 丽珠集团新北江制药股份有限公司 一种反应条件温和的奥贝胆酸制备方法
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
WO2020039449A1 (en) 2018-08-24 2020-02-27 Solara Active Pharma Sciences Limited An improved process for the preparation of obeticholic acid and intermediates used in the process thereof
KR20210089705A (ko) * 2018-11-08 2021-07-16 인터셉트 파마슈티컬즈, 인크. 오베티콜산의 사용 방법
CN109535217B (zh) * 2018-11-13 2020-04-14 丽珠集团新北江制药股份有限公司 一种奥贝胆酸的精制方法
CN113302190A (zh) 2019-01-15 2021-08-24 吉利德科学公司 Fxr(nr1h4)调节化合物
WO2020172075A1 (en) 2019-02-19 2020-08-27 Gilead Sciences, Inc. Solid forms of fxr agonists
BR112021024109A2 (pt) 2019-05-30 2022-03-22 Intercept Pharmaceuticals Inc Composições farmacêuticas compreendendo um agonista fxr e um fibrato para uso no tratamento de doença hepática colestática
MX2021014515A (es) 2019-05-31 2022-03-22 Sage Therapeutics Inc Esteroides neuroactivos y composiciones de estos.
WO2021029656A1 (ko) * 2019-08-14 2021-02-18 주식회사 바이오톡스텍 하이드로퀴논 유도체, 및 오베티콜릭산을 포함하는 비알콜성 지방간염의 예방 또는 치료용 약학조성물
CN112824425B (zh) * 2019-11-21 2023-10-03 成都西岭源药业有限公司 一种6-位烯基取代胆酸化合物及其制备方法和应用
US20230201222A1 (en) * 2020-05-13 2023-06-29 Children's Hospital Medical Center Alleviation of liver injury by activating the signaling pathway mediated by farnesoid x receptor
WO2022051321A1 (en) 2020-09-03 2022-03-10 Coherus Biosciences, Inc. Fixed dose combinations of chs-131 and a fxr agonist
KR102526452B1 (ko) * 2020-10-28 2023-04-27 (주)델로 관절 구조를 포함하는 토이 로봇
CN114644670A (zh) * 2020-12-17 2022-06-21 四川弘远药业有限公司 奥贝胆酸和对氨基苯甲酸的共晶及其制备方法
CN114236027B (zh) * 2021-12-22 2024-01-12 中山百灵生物技术股份有限公司 一种(E)-6-亚乙基-3α-羟基-7-酮基-5β-胆甾烷-24-酸的检测方法

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4072695A (en) 1972-09-21 1978-02-07 Intellectual Property Development Corporation 3α,7α-Dihydroxy-cholanic acid derivatives
IT1137459B (it) * 1981-04-14 1986-09-10 Erregierre Spa Prodesso per la preparazione di acido ursodeossicolico ad alta purezza
DE3366932D1 (en) 1982-07-29 1986-11-20 Lehner Ag New derivatives of biliary acids, process for the production thereof and pharmaceutical compositions containing the same
IT1206112B (it) 1983-04-29 1989-04-14 Lehner Ag Nuovi derivati di acidi biliari, procedimento per la loro preparazione e relative composizioni farmaceutiche.
IT1212835B (it) 1983-08-18 1989-11-30 Lehner Ag Derivati di acidi biliari, procedimento per la loro preparazione e relative composizioni farmaceutiche.
US4892868A (en) 1984-08-17 1990-01-09 Gipharmex, S.P.A. Derivatives of biliary acids, process for the production thereof and corresponding pharmaceutical compositions
IT1196377B (it) 1984-12-21 1988-11-16 Lehner Ag Derivati di acidi biliari,procedimento per la loro preparazione e relative composizioni farmaceutiche
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
IT1223313B (it) 1987-10-20 1990-09-19 Gipharmex Spa Derivati di acidi biliari loro preparazione e composizioni farmaceutiche che li contengono
JPH0320265A (ja) 1989-02-10 1991-01-29 Meiji Seika Kaisha Ltd アミノチアゾール酢酸誘導体並びにその製造法
IT1229570B (it) 1989-04-17 1991-09-04 Giuliani Spa Derivati fluorurati di acidi biliari, loro preparazione e composizioni farmaceutiche che li contengono.
US5175320A (en) 1989-04-17 1992-12-29 Giuliani S.P.A. Fluorinated bile acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
ES2074113T3 (es) 1989-12-13 1995-09-01 Mitsubishi Chem Corp Nuevos derivados de acido pirazolil acrilico, utiles como fungicidas sistemicos para la proteccion de plantas y materiales.
AU1856997A (en) 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
GB9604242D0 (en) 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
JP2000514807A (ja) 1996-07-12 2000-11-07 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー レプチン耐性の新規な治療
JP3600713B2 (ja) 1997-08-06 2004-12-15 東京応化工業株式会社 ポジ型ホトレジスト組成物
US6008237A (en) 1997-12-19 1999-12-28 Merck & Co., Inc. Arylthiazolidinedione derivatives
JP4253126B2 (ja) 1998-01-29 2009-04-08 アムジェン インコーポレイテッド Ｐｐａｒ−ガンマ調節剤
JP3146187B2 (ja) * 1998-06-26 2001-03-12 高砂香料工業株式会社 ジホスフィンオキシドの新規な製造方法
EP1137940A4 (en) 1998-10-23 2004-06-02 Glaxo Group Ltd METHOD FOR IDENTIFYING LIGANDS OF NUCLEAR RECEPTORS
US6639078B1 (en) 1998-12-23 2003-10-28 Smithkline Beecham Corporation Assays for ligands for nuclear receptors
AU2409600A (en) 1999-01-07 2000-07-24 Tularik Inc. Fxr receptor-mediated modulation of cholesterol metabolism
DE60013417T2 (de) 1999-03-26 2005-09-15 City Of Hope, Duarte Verfahren zum screenen von fxr-rezeptormodulatoren
US20020132223A1 (en) 1999-03-26 2002-09-19 City Of Hope Methods for modulating activity of the FXR nuclear receptor
EP1473042B1 (en) 1999-03-26 2006-06-21 City of Hope Screening for FXR receptor modulators
WO2000076523A1 (en) 1999-06-11 2000-12-21 Allergan Sales, Inc. Methods for modulating fxr receptor activity
US6906057B1 (en) 1999-06-11 2005-06-14 Allergan, Inc. Methods for modulating FXR receptor activity
US6559188B1 (en) 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
JP2003525217A (ja) 1999-10-22 2003-08-26 メルク エンド カムパニー インコーポレーテッド 肥満治療用薬剤
US6627636B2 (en) 2000-06-15 2003-09-30 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
WO2002020463A2 (en) 2000-09-05 2002-03-14 Tularik Inc. Fxr modulators
US20020119958A1 (en) 2001-02-13 2002-08-29 Shinichiro Tojo Therapeutic agent for hyperlipidemia
IL157816A0 (en) 2001-03-12 2004-03-28 Roberto Pellicciari Steroids as agonists for fxr
WO2002084286A1 (fr) 2001-04-12 2002-10-24 Takeda Chemical Industries, Ltd. Procede de criblage
WO2003016280A1 (en) 2001-08-13 2003-02-27 Lion Bioscience Ag Nr1h4 nuclear receptor binding compounds
EP1423113A4 (en) 2001-08-13 2007-04-18 Phenex Pharmaceuticals Ag NR1H4 NUCLEAR RECEPTOR BINDING COMPOUNDS
DE60131967D1 (de) 2001-08-13 2008-01-31 Phenex Pharmaceuticals Ag Nr1h4-kern-rezeptor-bindende verbindungen
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
CA2672549A1 (en) * 2001-11-14 2003-06-12 Ben-Zion Dolitzky Amorphous and crystalline forms of losartan potassium and process for their preparation
US20030144360A1 (en) 2001-11-19 2003-07-31 Allergan Sales, Inc. Composition and method for modulating BAR/FXR receptor activity
AU2003225903A1 (en) 2002-03-21 2003-10-08 Curagen Corporation Methods of using farnesoid x receptor (fxr) agonists
AU2003228485A1 (en) 2002-04-12 2003-10-27 The University Of Chicago Farnesoid x-activated receptor agonists
US6987121B2 (en) 2002-04-25 2006-01-17 Smithkline Beecham Corporation Compositions and methods for hepatoprotection and treatment of cholestasis
ITMI20021532A1 (it) 2002-07-12 2004-01-12 Roberto Pellicciari Composti chimici
JP2006515838A (ja) 2002-11-22 2006-06-08 スミスクライン ビーチャム コーポレーション ファルネソイドｘ受容体アゴニスト
US20070015796A1 (en) 2003-09-26 2007-01-18 Smithkline Beecham Corporation Compositions and methods for treatment of fibrosis
EP1568706A1 (en) * 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Novel steroid agonist for FXR
EP1758608A2 (en) * 2004-03-11 2007-03-07 Fresenius Kabi Deutschland GmbH Conjugates of hydroxyethyl starch and erythropoietin
EP1734970B1 (en) 2004-03-12 2014-12-31 Intercept Pharmaceuticals, Inc. Treatment of fibrosis using fxr ligands
JP2008509912A (ja) * 2004-08-10 2008-04-03 エグゼリクシス， インコーポレイテッド 医薬品としての複素環化合物
US20060252670A1 (en) * 2004-10-14 2006-11-09 Intercept Pharmaceuticals Inc. Method of reducing drug-induced adverse side effects in a patient
JP2008539243A (ja) * 2005-04-25 2008-11-13 ジェネーラ・コーポレーション スクアラミンジラクテートの多形塩形態および無定形塩形態
ITMI20050912A1 (it) 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
JP2007077123A (ja) 2005-09-16 2007-03-29 Shiono Chemical Co Ltd 非晶質セフジニル、その製造方法およびこれを含有する経口投与用医薬組成物
SI2040713T1 (sl) 2006-06-27 2014-11-28 Intercept Pharmaceuticals, Inc. Derivati žolčne kisline kot FXR ligandi za preprečevanje ali zdravljenje bolezni ali stanj, posredovanih s FXR
EP1894924A1 (en) * 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
CL2007003035A1 (es) * 2006-10-24 2008-05-16 Smithkline Beechman Corp Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos,
EP2112995B1 (en) 2007-01-19 2013-07-31 Intercept Pharmaceuticals, Inc. 23-substituted bile acids as tgr5 modulators and methods of use thereof
EP1947108A1 (en) 2007-01-19 2008-07-23 Intercept Pharmaceuticals, Inc. TGR5 modulators and methods of use thereof
US8338628B2 (en) 2007-08-28 2012-12-25 City Of Hope Method of synthesizing alkylated bile acid derivatives
JP5222953B2 (ja) * 2007-11-15 2013-06-26 エフ．ホフマン−ラ ロシュ アーゲー ベンゾイミダゾール誘導体及びｆｘｒアゴニストとしてのその使用
CN102164940B (zh) 2008-07-30 2015-08-19 英特塞普特医药品公司 Tgr5调节剂及其使用方法
WO2010039529A2 (en) * 2008-09-23 2010-04-08 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treament of inflammatory disease
CA2744189C (en) 2008-11-19 2016-10-11 Intercept Pharmaceuticals, Inc. Tgr5 modulators and methods of use thereof
EP2470553A4 (en) 2009-08-25 2013-02-20 British Columbia Cancer Agency POLYHYDROXYLATED BILIARY ACIDS FOR THE TREATMENT OF BILIARY DISORDERS
CN102121547B (zh) * 2010-12-23 2013-01-16 拉卡萨安吉拉股份有限公司 用于管道接头的衬套和采用该衬套的管道接头
CN102372757B (zh) * 2011-10-31 2013-01-16 安徽科宝生物工程有限公司 酯化法制备猪胆汁中鹅去氧胆酸的方法
EP3336097B1 (en) 2012-06-19 2020-08-19 Intercept Pharmaceuticals, Inc. Preparation of the non-crystalline form of obeticholic acid

Also Published As

Publication number Publication date
IL236231A0 (en) 2015-02-01
CL2014003475A1 (es) 2015-08-07
AU2020202405A1 (en) 2020-04-30
AU2013277429B2 (en) 2016-01-14
JP6877389B2 (ja) 2021-05-26
EP2861613A1 (en) 2015-04-22
SG10201607230SA (en) 2016-10-28
BR112014031828A2 (pt) 2021-07-06
US20190153020A1 (en) 2019-05-23
TWI673284B (zh) 2019-10-01
PL3336097T3 (pl) 2021-05-31
CA2877122C (en) 2020-04-28
AU2017204057B2 (en) 2018-11-01
EA201990211A1 (ru) 2019-06-28
CA3047776A1 (en) 2013-12-27
ES2822375T3 (es) 2021-04-30
TW201410699A (zh) 2014-03-16
WO2013192097A1 (en) 2013-12-27
BR122016011808B1 (pt) 2021-09-21
EP3992201A1 (en) 2022-05-04
US10047117B2 (en) 2018-08-14
MX2019005819A (es) 2019-10-21
JP2016074724A (ja) 2016-05-12
EP3789394A1 (en) 2021-03-10
PH12014502835A1 (en) 2015-02-02
JP2020125317A (ja) 2020-08-20
CO7240414A2 (es) 2015-04-17
US20170226149A1 (en) 2017-08-10
CL2015002145A1 (es) 2015-12-11
EP3336097A1 (en) 2018-06-20
US20160215014A1 (en) 2016-07-28
AU2018241172A1 (en) 2018-11-01
AU2016200832B2 (en) 2017-05-18
KR20190121871A (ko) 2019-10-28
IL257841A (en) 2018-04-30
AU2013277429A1 (en) 2015-01-22
JP2018172438A (ja) 2018-11-08
IN2014MN02561A (es) 2015-09-04
AU2018241172B2 (en) 2020-03-05
JP6978544B2 (ja) 2021-12-08
EA201590040A1 (ru) 2015-05-29
IL261372A (en) 2018-10-31
KR20160143894A (ko) 2016-12-14
PT3336097T (pt) 2020-10-29
SG11201408501UA (en) 2015-01-29
US20160074419A1 (en) 2016-03-17
KR101881245B1 (ko) 2018-07-23
NZ734451A (en) 2018-12-21
CN111228278A (zh) 2020-06-05
AU2017204057A1 (en) 2017-07-06
US10174073B2 (en) 2019-01-08
EP3336097B1 (en) 2020-08-19
NZ719360A (en) 2017-08-25
US20210395293A1 (en) 2021-12-23
BR112014031828B1 (pt) 2021-12-21
DK3336097T3 (da) 2020-09-28
US20160176913A1 (en) 2016-06-23
NZ703072A (en) 2016-06-24
US10155787B2 (en) 2018-12-18
KR20150022974A (ko) 2015-03-04
JP2018184443A (ja) 2018-11-22
EA032347B1 (ru) 2019-05-31
SI3336097T1 (sl) 2021-07-30
BR122016011808A2 (pt) 2018-12-11
JP6527077B2 (ja) 2019-06-05
US9238673B2 (en) 2016-01-19
US20230340010A1 (en) 2023-10-26
SG10201610434YA (en) 2017-02-27
JP2017075169A (ja) 2017-04-20
MX365059B (es) 2019-05-22
JP2015521621A (ja) 2015-07-30
AU2016200832A1 (en) 2016-02-25
US20130345188A1 (en) 2013-12-26
CA3028207A1 (en) 2013-12-27
MX2014016062A (es) 2015-07-17
CN104781272A (zh) 2015-07-15
US9732116B2 (en) 2017-08-15
CA2877122A1 (en) 2013-12-27
CA3047776C (en) 2022-10-18
KR20180083966A (ko) 2018-07-23

Similar Documents

Publication Publication Date Title
IL261372A (en) Preparations, uses and solid forms of obeticholic acid
HK1209157A1 (en) Extraction, preparation, and application of plant micro-ribonucleic acid
HK1212701A1 (zh) 恩雜魯胺製劑
EP2903939A4 (en) STABLE PERCARBOXYLIC ACID COMPOSITIONS AND USES THEREOF
EP2836604A4 (en) PROCESS FOR PREPARING NANOPORE, AND USES THEREOF
HUE038664T2 (hu) Hialuronsav C6-C18-acilezett származéka, eljárás annak elõállítására, erre épülõ nanomicelláris kompozíció, eljárás annak elõállítására és eljárás stabilizált nanomicelláris kompozíció elõállítására, valamint annak alkalmazása
EP2718331A4 (en) N, N, N-TRIALKYL POLYMERS, METHODS FOR THEIR PREPARATION, AND USES THEREOF
HK1207824A1 (en) Polymorph compositions, methods of making, and uses thereof
PL2934134T3 (pl) Zastosowania inhalacji kwasem acetylosalicylowym
IL236312A0 (en) Preparation of 18f-flucyclobin
ZA201504167B (en) Processes for the preparation of 4-amino-3-halo-6- (substituted)picolinates and 4-amino-5-fluoro-3-halo-6- (substituted)picolinates
IL236965B (en) Derivatives of 5-aminolevulinic acid and uses thereof
EP2813495A4 (en) 2-ARYLBENZOFURAN-7-FORMAMIDE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND USE THEREOF
EP2903979A4 (en) Novel compounds, their preparation and use
EP2805956A4 (en) GAMBOGIC ACID DERIVATIVES, PREPARATION METHOD AND APPLICATION THEREOF
EP2892529A4 (en) USES OF (-) - PERHEXILINE
HK1216891A1 (zh) 苔蘚素組合物、其製備方法和用途
SG11201405376TA (en) CRYSTALLINE FORMS OF 5α-ANDROSTANE-3β, 5, 6β-TRIOL AND PREPARATION METHODS THEREOF
HK1217670A1 (zh) 調配物、其製造方法和用途
EP2837632A4 (en) COMPOUND JK12A AND ITS PREPARATION
EP2870133A4 (en) TETRAHYDRO ISOHUMULOD DERIVATIVES, METHOD FOR THE PREPARATION AND USE THEREOF